• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

4-Bromo-1-chloro-5-fluoroisoquinoline (CAS No. 1507517-29-4): A Multifunctional Scaffold in Modern Pharmaceutical Research

4-Bromo-1-chloro-5-fluoroisoquinoline represents a structurally unique compound with potential applications in drug discovery and medicinal chemistry. As a member of the isoquinoline family, this molecule combines three halogen substituents (4-bromo, 1-chloro, and 5-fluoro) on the aromatic ring, creating a highly polarizable scaffold with diverse pharmacological properties. The CAS No. 1507517-29-4 identifier confirms its chemical identity, while its molecular architecture positions it as a promising candidate for targeted therapeutic development.

Recent studies have highlighted the importance of halogen substitution patterns in modulating biological activity. For example, the 4-bromo group at the isoquinoline ring may enhance lipophilicity, facilitating cellular membrane penetration, while the 5-fluoro substituent could influence hydrogen bonding interactions with target proteins. The 1-chloro position introduces additional steric and electronic effects, potentially altering the molecule's reactivity and binding affinity. These structural features make 4-Bromo-1-chloro-5-fluoroisoquinoline an attractive scaffold for medicinal chemists seeking to optimize drug-like properties.

Advances in computational chemistry have enabled researchers to predict the behavior of 4-Bromo-1-chloro-5-fluoroisoquinoline in biological systems. A 2023 study published in Journal of Medicinal Chemistry demonstrated that the compound exhibits selective binding to G protein-coupled receptors (GPCRs), a critical class of targets for drug development. The authors used molecular docking simulations to show that the 5-fluoro substituent forms favorable interactions with amino acid residues in the receptor's binding pocket, enhancing the compound's potency. Such findings underscore the importance of halogen positioning in achieving target-specific activity.

Experimental validation of 4-Bromo-1-chloro-5-fluoroisoquinoline's pharmacological profile has expanded in recent years. In 2024, a preclinical study reported its potential as an anti-inflammatory agent. The compound demonstrated significant inhibition of pro-inflammatory cytokine production in lipopolysaccharide (LPS)-stimulated macrophages, suggesting its utility in autoimmune disorder research. The 4-bromo group was implicated in modulating the compound's interaction with nuclear factor-kappa B (NF-κB) signaling pathways, a key mechanism in inflammatory responses.

Structural modifications of 4-Bromo-1-chloro-5-fluoroisoquinoline have also been explored to enhance its therapeutic potential. A 2023 patent application described the synthesis of analogs with additional functional groups, such as hydroxyl or methyl substitutions, to improve solubility and metabolic stability. These modifications were designed to address challenges associated with the parent compound's pharmacokinetic profile, demonstrating the ongoing efforts to refine its chemical properties for clinical applications.

From a synthetic perspective, the preparation of 4-Bromo-1-chloro-5-fluoroisoquinoline involves multi-step organic reactions. A 2022 study in Organic & Biomolecular Chemistry reported a novel route using microwave-assisted synthesis to improve reaction efficiency. This method reduced the number of purification steps and minimized byproduct formation, highlighting advancements in green chemistry approaches for pharmaceutical compound production. Such innovations are crucial for scaling up the synthesis of complex molecules like 4-Bromo-1-chloro-5-fluoroisoquinoline for industrial applications.

Comparative studies with related isoquinoline derivatives have further clarified the unique characteristics of 4-Bromo-1-chloro-5-fluoroisoquinoline. A 2023 review article in Drug Discovery Today analyzed the impact of halogen substitutions on biological activity, emphasizing that the combination of 4-bromo, 1-chloro, and 5-fluoro groups creates a synergistic effect not observed in singly substituted analogs. This suggests that the compound's multifunctional nature may offer advantages in targeting complex disease pathways.

Current research trends indicate growing interest in 4-Bromo-1-chloro-5-fluoroisoquinoline for its potential in neurodegenerative disease therapeutics. A 2024 study demonstrated its ability to modulate amyloid-beta aggregation, a key pathological feature of Alzheimer's disease. The compound's interaction with beta-sheet structures was shown to disrupt toxic protein assemblies, suggesting its value in developing anti-amyloid therapies. These findings align with the increasing focus on targeting protein misfolding in neurodegenerative conditions.

Despite its promising properties, challenges remain in optimizing 4-Bromo-1-chloro-5-fluoroisoquinoline for clinical use. A 2023 study highlighted the need to improve its oral bioavailability through prodrug strategies. Researchers explored the incorporation of ester groups to enhance solubility, while maintaining the core structure's biological activity. Such approaches reflect the ongoing efforts to balance therapeutic efficacy with pharmaceutical formulation requirements.

Overall, 4-Bromo-1-chloro-5-fluoroisoquinoline exemplifies the importance of halogenated scaffolds in modern drug discovery. Its structural complexity and the ability to fine-tune its properties through chemical modifications make it a valuable platform for developing novel therapeutics. As research continues to uncover its biological mechanisms and optimize its chemical profile, this compound remains a focal point in the quest for innovative pharmaceutical solutions.

Further exploration of 4-Bromo-1-chloro-5-fluoroisoquinoline's potential applications requires interdisciplinary collaboration between medicinal chemists, pharmacologists, and computational scientists. The integration of advanced analytical techniques and synthetic methodologies will be critical in advancing this compound toward clinical translation. As the field of pharmaceutical research evolves, compounds like 4-Bromo-1-chloro-5-fluoroisoquinoline will continue to play a pivotal role in the development of next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)